内容

目次

List of Contributors; Forewords; Preface; List of Abbreviations; Part I. Biology of Endonucleases (Zinc-Finger Nuclease, TALENs and CRISPRs) and Regulatory Networks: 1. Introduction to Genome Editing and Engineering: From Talens, ZFNs and CRISPRs to Molecular Surgery; 2. Targeted Genome Editing Techniques in C. elegans and Other Nematode Species; 3. Unbiased Detection of Off-Target Cleavage by CRISPR-Cas9 and TALENs Using Integrase-Defective Lentiviral Vectors; 4. In Vivo Studies of miRNA Target Interactions Using Site-Specific Genome Engineering; 5. Don't Kill the Messenger: Employing Genome Editing to Study Regulatory RNA Interactions; Part II. Genome Editing in Model Organisms: 6. Genome Editing in the Crustacean Daphnia magna Using Crispr/Cas and TALEN Systems; 7. Leapfrogging: A Method for Targeting Genome Editing to the Germline; 8. Genome Editing with Desired Mutations (Knock-In) by CRISPR in Model Organisms; 9. Genetically Engineered Pig Models for Human Diseases Using ZFNs, TALENs and CRISPR-Cas9; 10. Gene Editing to Create Agricultural and Biomedical Swine Models; 11. Generation of New Model Cell Lines Using ssODNknockindonors and FACS-based Genome Editing; Part III. Technology Development and Screening: 12. CRISPR Genome Editing in Mice; 13. Detection of Insertion/Deletion (indel) Events after Genome Targeting: Pros and Cons of the Available Methods; 14. Application of TAL Proteins and the CRISPR System to Purification of Specific Genomic Regions for Locus-Specific Identification of Chromatin-Associated Molecules; 15. Application of CRISPR for Pooled, Vector-Based Functional Genomic Screening in Mammalian Cell Lines; 16. Generation and Utilization of CRISPR/Cas9 Screening Libraries in Mammalian Cells; Part IV. Genome Editing in Stem Cells and Regenerative Biology: 17. Targeted Genome Editing Using Nuclease Assisted Vector Integration; 18. Genome Engineering Using Sleeping Beauty Transposition in Vertebrates; 19. Genome Editing of Pluripotent Stem Cells; 20. Principles for Targeting Adult Tissue Stem Cells to Achieve Durable Gene and Gene-Editing Therapies; 21. Therapeutic Genome Editing in Human Hematopoietic Stem and Progenitor Cells; Part V. Genome Editing in Disease Biology: 22. CRISPR/Cas9-Based In Vivo Models of Cancer; 23 Inducible CRISPR-Based Genome Editing for the Characterization of Cancer Genes.; 24 Genome Editing in Retinal Diseases.; 25. Manipulation of Long Non-Coding RNAs in Cardiovascular Disease Using Genome-Editing Technology; 26. Gene Silencing, Disruption and Latency Reactivation with RNA-based and Gene Editing CRISPR/Cas, ZFN and TALEN Technologies for HIV-1/AIDS Therapies; 27. Use of the CRISPR-Cas9 System for Genome Editing of Immune System Cells, Defense against HIV-1 and Cancer Therapies; 28. Harnessing Therapeutic Potential of Long Non-Coding RNAs in Immunity; Part VI. Legal (Intelluctual Property) and Bioethical Issues of Genome Editing: 29. Patening of CRISPR-Based Inventions; 30. Patent, Ownership, and Licensing Issues of CRISPR-Based Genome Editing: Impact on Universities and their Licensees; 31. The Ethics of Human Genome Editing; 32. Regulating Human Genome Editing: Negotiating Ethical Concerns through Science and Policy; Index.